Eli Lilly’s Oral Orforglipron Study Completion Signals Next Step in Diabetes and Obesity Market Race
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly and Co. (LLY) has completed a Phase 3 study titled “A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk.” The goal was to see how well daily oral orforglipron works and how safe it is versus injectable insulin glargine in higher risk patients.
The trial tested two drugs. One is orforglipron, an oral once-daily medicine also known as LY3502970, designed to improve blood sugar control and support weight loss in adults with type 2 diabetes. The other is insulin glargine, a standard injectable basal insulin used as an active comparator and titrated to target glucose levels.
The study used a randomized, parallel-group design, which means people were split by chance into two separate treatment groups and followed over time. It was open-label, so both doctors and participants knew which drug they were getting, and the main goal was treatment focused, measuring control of diabetes and overall safety.
The study was first submitted on March 27, 2023, marking the formal start of the program in the public record. The trial is now listed as completed, and the last update on April 16, 2026 signals that Lilly has finalized key data checks and is preparing for analysis, publication, or regulatory use.
For investors, a positive Phase 3 readout for oral orforglipron could support LLY’s premium valuation in diabetes and obesity care and extend its lead in GLP-1–related therapies. It may also pressure rivals in diabetes and weight-loss markets, including other large pharma names, as the shift from injections to oral options could reshape long-term demand patterns.
The study is completed and recently updated on the public record, and more detailed information will be available as results are posted on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.
